ARCH Venture Partners

What ARCH Venture Partners does

ARCH Venture Partners is a privately held venture capital firm headquartered in Chicago, Illinois, with a second office in Mercer Island (Seattle), Washington. Founded in 1986 by Steven Lazarus at the University of Chicago and Argonne National Laboratory as the Argonne-Chicago (ARCH) Development Corporation to commercialize academic and national laboratory research, the firm was reorganized as a private partnership in 1992. ARCH specializes in the early-stage formation, funding, and development of disruptive life sciences and technology companies, co-founding businesses alongside leading scientists and entrepreneurs and providing multi-stage capital from as little as $50K at seed to hundreds of millions of dollars per company. The firm operates a series of venture capital funds — most recently ARCH Venture Fund XIII at more than $3 billion (September 2024), preceded by Fund XII ($2.975B, 2022), Fund XI ($1.85B+, 2021), and Funds X and X Overage ($1.46B combined, 2020) — and has built more than 230 portfolio companies across biotechnology, life sciences tools, AI-driven drug discovery, quantum computing, and physical AI.

ARCH generates revenue through management fees on committed fund capital and carried interest on successful portfolio exits, a standard venture capital economic model. Its capital is sourced from institutional limited partners including endowments, family offices, sovereign wealth funds, and other institutional investors via private placement. Beyond its funds, the firm operates ARCH Strategic Partnerships (ASP), an initiative providing consulting services to corporate industry leaders to foster relationships with early-stage scientific innovators and surface dealflow — a complementary revenue and partnership channel to the firm's core company-co-founding model. Go-to-market is relationship-driven: deal sourcing depends on ARCH's network of academic institutions (notably the University of Chicago and Argonne National Laboratory), national research laboratories, corporate research groups, and repeat entrepreneurs, with the firm typically leading or co-leading rounds and taking board seats. Notable portfolio companies include Illumina, Alnylam Pharmaceuticals, Juno Therapeutics, Vir Biotechnology, Karuna Therapeutics, Beam Therapeutics, Sana Biotechnology, Twist Bioscience, GRAIL, Xaira Therapeutics, Prometheus, and D-Wave (via Quantum Circuits), with co-founder Robert Nelsen having personally played a role in more than 150 company creations.

The firm is led by co-founders and Managing Directors Robert Nelsen, Keith Crandell, and Clinton Bybee (Emeritus), with additional Managing Directors Kristina Burow, Steve Gillis, Paul Berns, and Mark McDonnell (CFO and CAO), supported by a deep bench of Partners, Venture Partners, and Senior Advisors including John Maraganore (founding CEO of Alnylam) and Brian Cuneo (former Latham & Watkins Life Sciences chair). ARCH has expanded its geographic reach globally — with portfolio companies in the US, UK, China, Sweden, Singapore, and Switzerland — and has broadened its thematic scope from biotech into AI-driven drug discovery, quantum computing, and physical AI through flagship investments such as Xaira Therapeutics, Prometheus, and Quantum Circuits.

Name

ARCH Venture Partners

Legal name

ARCH Venture Partners

Website

http://www.archventure.com

Company type

Private

Founded year

1986

Operating status

Operating

Headcount range

11–50 employees

Short description

ARCH Venture Partners is an early-stage venture capital firm founded in 1986 that co-founds and invests in life sciences, biotechnology, AI, and deep-tech companies, providing multi-stage capital from seed to commercial stages across 230+ portfolio companies worldwide.

Ownership category

akta.pro rank

Product category

Venture Capital

akta.pro primary industry

Venture Capital Fund-of-Funds / Multi-Manager Platforms (FSANAAAJ)

akta.pro secondary industry

Venture Capital Fundraising Placement (FSAEALAC)

Keywords

• Venture capital funding
• Biotechnology investment
• Life sciences venture
• Early-stage company building
• Academic technology commercialization

Headquarters

HQ city

Chicago

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Marketing or Sales, Others

Revenue model

1. Venture fund management and carried interest: ARCH Venture Partners generates revenue as a venture capital firm through management fees on committed fund capital and carried interest (equity participation) on successful exits from portfolio companies. The firm has raised multiple multi-billion-dollar funds (Fund VIII through Fund XIII) ranging from $560 million to $3 billion each, investing primarily in companies it co-founds with leading scientists and entrepreneurs.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Core offering

ARCH Venture Partners is a venture capital firm that co-founds and invests in early-stage life sciences, physical sciences, and technology companies, deploying multi-stage capital ranging from $50,000 to hundreds of millions of dollars per company. The firm raises and manages a series of venture capital funds (Fund VIII through Fund XIII) from institutional limited partners and partners with leading scientists, entrepreneurs, academic institutions, and national laboratories to commercialize breakthrough research into viable companies. ARCH Strategic Partnerships (ASP) supplements the funds by providing consulting services to corporate industry leaders seeking collaboration with early-stage scientific innovators.

Product overview

ARCH Venture Partners is an early-stage technology venture firm that creates and invests in groundbreaking life science and technology companies. Its offerings center on a series of venture capital funds — most recently ARCH Venture Fund XIII ($3B+), preceded by Fund XII ($2.975B), Fund XI ($1.85B+), and Fund X and Fund X Overage (combined $1.46B) — that finance the founding and growth of disruptive early-stage biotechnology companies. Complementing the funds, ARCH Strategic Partnerships (ASP) is a consulting initiative that helps corporations collaborate with early-stage scientific innovators and bring discoveries to market. Together, the funds provide the capital foundation for ARCH's portfolio of more than 230 companies, while ASP extends the firm's expertise into corporate venture building.

Differentiator

Problem solved

Functional benefit

Brands

• ARCH Strategic Partnerships (ASP): An ARCH initiative that provides consulting services to corporations building innovation-driven technology commercialization and business development practices globally, fostering relationships between industry leaders and early-stage scientific innovators.

Products and services

• ARCH Venture Fund XIII A venture capital fund with more than $3 billion committed to support the founding and growth of early-stage biotechnology companies; to-date investments include ArsenalBio, Metsera, Mirador Therapeutics, and Xaira Therapeutics.
• ARCH Venture Fund XII A $2.975 billion venture capital fund to invest in the creation, development, and funding of early-stage biotechnology companies across infectious disease, mental health, immunology, oncology, neurology, age-related diseases, manufacturing, clinical trials, genomic and biological tools, data sciences, diagnostics, and therapies.
• ARCH Venture Fund XI A venture capital fund with over $1.85 billion committed to invest in the creation and funding of early-stage biotechnology companies working on infectious disease, mental health, immunology, oncology, neurology, manufacturing, clinical trials, anti-aging medicines, genomic and biological tools, data sciences, diagnostics, and therapies.
• ARCH Venture Fund X and Fund X Overage Two paired venture capital funds with a combined $1.46 billion to invest in transformative, early-stage biotechnology companies; the Overage is deployed in fewer deals requiring larger investments.
• ARCH Strategic Partnerships (ASP) A consulting and corporate-relations initiative that helps corporations build innovation-driven technology commercialization and business development practices, providing access to ARCH's dealflow and early-stage scientific innovators for collaboration.

Quantifiable outcome

• More than 230 companies built since 1986
• +2 more outcomes

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Eight partnerships are on record, tiered flagship, core and minor.

• Project Prometheus (Bezos-backed physical AI)flagshipStrategic or Co-development Partner · 15 June 2026ARCH participated in Prometheus's $12 billion Series B at a $41 billion valuation, alongside JPMorgan Chase, Goldman Sachs, BlackRock, DST Global, and Bezos. ARCH co-founder Robert Nelsen is co-founder of Project Prometheus and serves as a director. Prometheus is developing an "artificial general engineer" to automate design and manufacturing.
• Massachusetts General Hospital (MGH)coreStrategic or Co-development Partner · 28 January 2026Massachusetts General Hospital is the source institution for Altido Bio's CAR-T therapy for glioblastoma. ARCH led Altido Bio's $12.5 million seed round to advance an MGH-developed CAR-T therapy. ARCH maintains broader strategic ties to Mass General via Keith Crandell's role on the Mass General Brigham Innovation Fund Investment Advisory Board.
• ARCH Strategic Partnerships (ASP) corporate partnerscoreStrategic or Co-development Partner · 1 January 2026ARCH Strategic Partnerships (ASP) is an ARCH initiative providing consulting services to corporate industry leaders and fostering relationships between them and early-stage scientific innovators. ASP corporate partners gain access to innovation, dealflow, industry experts, collaborations, and have started corporate venture capital teams. They strategically partner with innovative companies in the ARCH portfolio and beyond.
• Polsky Center for Entrepreneurship, Chicago Booth / University of Chicago Pritzker School of Molecular EngineeringcoreStrategic or Co-development Partner · 1 January 2026ARCH co-founder Keith Crandell has served on the Entrepreneurship Advisory Board at the Polsky Center for Entrepreneurship at ChicagoBooth since 2005 and on the University of Chicago Pritzker School of Molecular Engineering Advisory Council since 2017. These partnerships support ARCH's pipeline of academic spinouts.
• D-Wave QuantumminorStrategic or Co-development Partner · 6 November 2025D-Wave Quantum acquired ARCH-backed Quantum Circuits to accelerate the development of quantum computers (announced January 7, 2026). Quantum Circuits was originally co-founded by ARCH, F-Prime, Sequoia Capital, and Hither Creek Ventures.
• University of Chicago / Argonne National LaboratorycoreStrategic or Co-development Partner · 26 September 2024Founding institutional partnership. ARCH was created in 1986 by Steven Lazarus at the University of Chicago with Walter Massey and the Trustees, originally as the Argonne-Chicago (ARCH) Development Corporation, to commercialize technologies developed at these institutions. Keith Crandell serves on the Polsky Center for Entrepreneurship Advisory Board and the University of Chicago Pritzker School of Molecular Engineering Advisory Council. The firm remains "a recognized leader in commercializing technologies developed at academic institutions, corporate research groups and national laboratories."
• Endpoints 11 (Dispatch Bio and Sironax) — 2025 winnersminorOthers · 26 September 2024Two ARCH-backed companies — Dispatch Bio and Sironax — named to the Endpoints 11 list of most exciting startups in 2025, validating ARCH's biotech portfolio.
• Irish government consortiumminorStrategic or Co-development Partner · 1 January 2011ARCH established its European office in Dublin, Ireland in 2011 led by the late Managing Director Paul Thurk, working with an Irish government consortium to identify and build businesses from Ireland-based academic institutions. Resulted in co-founding of Carrick Therapeutics, Genomics Medicine Ireland, and Pretzel Therapeutics.

Scale indicators12 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Flagship Pioneering: Flagship Pioneering is the closest direct peer — a private venture firm that creates and funds platform biotech companies (Moderna, Generate Biomedicines, Tessera Therapeutics) from proprietary science, raising large multi-billion-dollar funds. Both ARCH and Flagship operate a company-creation (rather than traditional financial-investor) model, co-found breakthrough life sciences ventures, and invest from inception through public stages.
• Third Rock Ventures: Third Rock Ventures is a direct peer — a biotech-focused venture firm that builds companies from scratch around breakthrough science, similar to ARCH's company-creation approach. Both firms co-found life sciences companies, take deep operational roles, and focus on platform technologies in therapeutics and diagnostics.
• Atlas Venture: Atlas Venture is a direct peer — an early-stage biotech venture firm that builds and funds breakthrough therapeutics companies from inception. Like ARCH, Atlas focuses on company creation, takes board seats, and concentrates on life sciences with concentrated portfolio construction around platform technologies.
• OrbiMed: OrbiMed is a direct peer — a healthcare-dedicated investment firm managing multi-billion-dollar funds across the life sciences continuum from venture to public equity. Like ARCH, OrbiMed invests across stages in biotech, medical devices, and diagnostics, and is a frequent co-investor in ARCH's portfolio companies.
• RA Capital Management: RA Capital is a direct peer — a healthcare-focused investment manager that combines venture capital with public equity and crossover investing. RA Capital is one of ARCH's most frequent co-investors (Parabilis, Ollin, nChroma), making the two firms directly comparable in stage, focus, and syndicate behavior.
• Versant Ventures: Versant Ventures is a direct peer — a healthcare-focused venture firm that builds biotech companies from inception with offices in North America and Europe. Like ARCH, Versant operates a company-creation model, often co-founds ventures around academic science, and deploys multi-hundred-million-dollar funds concentrated in therapeutics.
• Andreessen Horowitz (a16z Bio+Health): Andreessen Horowitz's Bio+Health fund is an emerging direct peer — a major generalist VC that has aggressively expanded into early-stage biotech and digital health with multi-billion-dollar dedicated funds. a16z Bio+Health participates in many of ARCH's later rounds (e.g., Ollin Biosciences, Xaira) and competes for the same early-stage company-creation deals.
• Foresite Capital: Foresite Capital is a direct peer — a healthcare and life sciences-focused investment firm that has built and backed multiple biotech platforms from early stage to IPO. Like ARCH, Foresite concentrates on breakthrough science with deep operating involvement, often co-founding companies around novel therapeutics.
• Deerfield Management: Deerfield Management is a direct peer — a healthcare-focused investment firm with multiple fund vehicles covering public and private biotech, medical devices, and healthcare services. Like ARCH, Deerfield invests across all stages of company development in life sciences and frequently co-invests in ARCH-led rounds.

Emerging players

• Lux Capital: Lux Capital is an emerging peer in life sciences venture — primarily a deep-tech investor that has built out a life sciences practice investing in biotech, neurotechnology, and healthcare AI. Lux is a frequent co-investor with ARCH (e.g., Paradigm Health), though it maintains a broader technology focus beyond biotech.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xtwitter.com/ARCHVenture
• LinkedInlinkedin.com/company/avpvc
• Facebookfacebook.com/328070648007804

Revenue estimate

Valuation estimate

Number of profiles

Profiles15 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments564 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ARCH Venture Partners